Biogen Inc. (BIIB) Shares Bought by Linscomb & Williams Inc.

Linscomb & Williams Inc. increased its stake in Biogen Inc. (NASDAQ:BIIB) by 2.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,204 shares of the biotechnology company’s stock after buying an additional 29 shares during the period. Linscomb & Williams Inc.’s holdings in Biogen were worth $327,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Beacon Trust Co. boosted its holdings in Biogen by 0.5% in the first quarter. Beacon Trust Co. now owns 1,135 shares of the biotechnology company’s stock worth $328,000 after purchasing an additional 6 shares during the period. Guardian Life Insurance Co. of America boosted its holdings in Biogen by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 839 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 6 shares during the period. Carroll Financial Associates Inc. boosted its holdings in Biogen by 1.2% in the second quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 6 shares during the period. Buckingham Capital Management Inc. boosted its holdings in Biogen by 0.3% in the first quarter. Buckingham Capital Management Inc. now owns 2,452 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 8 shares during the period. Finally, RMB Capital Management LLC boosted its holdings in Biogen by 1.1% in the first quarter. RMB Capital Management LLC now owns 814 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 9 shares during the period. Institutional investors and hedge funds own 87.65% of the company’s stock.

Biogen (NASDAQ:BIIB) last announced its earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 EPS for the quarter, topping the consensus estimate of $4.36 by $0.68. The company had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $2.81 billion. Biogen had a return on equity of 37.42% and a net margin of 28.10%. The business’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.21 earnings per share.

WARNING: This report was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://sportsperspectives.com/2017/10/12/biogen-inc-biib-shares-bought-by-linscomb-williams-inc.html.

BIIB has been the subject of a number of research reports. Vetr raised shares of Biogen from a “buy” rating to a “strong-buy” rating and set a $311.67 price objective for the company in a report on Tuesday, June 27th. Deutsche Bank AG initiated coverage on shares of Biogen in a report on Friday, June 23rd. They issued a “buy” rating and a $315.00 price objective for the company. Robert W. Baird reaffirmed a “hold” rating and issued a $290.00 price objective on shares of Biogen in a report on Friday, August 25th. Credit Suisse Group set a $300.00 price objective on shares of Biogen and gave the stock a “hold” rating in a report on Friday, July 14th. Finally, BMO Capital Markets lifted their price objective on shares of Biogen from $328.00 to $377.00 and gave the stock a “market perform” rating in a report on Wednesday, September 13th. Thirteen equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. Biogen currently has an average rating of “Buy” and an average target price of $331.49.

In other news, EVP Susan H. Alexander sold 7,758 shares of the stock in a transaction on Wednesday, July 19th. The stock was sold at an average price of $285.00, for a total transaction of $2,211,030.00. Following the sale, the executive vice president now owns 27,232 shares in the company, valued at $7,761,120. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Susan H. Alexander sold 4,974 shares of the stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total value of $1,442,509.74. Following the sale, the executive vice president now owns 22,258 shares in the company, valued at approximately $6,455,042.58. The disclosure for this sale can be found here. 0.25% of the stock is currently owned by corporate insiders.

Biogen Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply